Literature DB >> 21628620

Antiparasitic therapy.

Shanthi Kappagoda1, Upinder Singh, Brian G Blackburn.   

Abstract

Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628620      PMCID: PMC3104918          DOI: 10.4065/mcp.2011.0203

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  126 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

3.  The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease.

Authors:  J Antonio Marin-Neto; Anis Rassi; Alvaro Avezum; Antonio C Mattos; Anis Rassi; Carlos A Morillo; Sergio Sosa-Estani; Salim Yusuf
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

4.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

Review 5.  Loiasis: African eye worm.

Authors:  Jeannie J Padgett; Kathryn H Jacobsen
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-05-07       Impact factor: 2.184

Review 6.  Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis.

Authors:  Achim Hoerauf
Journal:  Curr Opin Infect Dis       Date:  2008-12       Impact factor: 4.915

7.  Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.

Authors:  Gerardo Priotto; Loretxu Pinoges; Isaac Badi Fursa; Barbara Burke; Nathalie Nicolay; Guillaume Grillet; Cathy Hewison; Manica Balasegaram
Journal:  BMJ       Date:  2008-03-05

8.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13

9.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28

10.  Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine.

Authors:  Alexander C Aichelburg; Julia Walochnik; Ojan Assadian; Helmut Prosch; Andrea Steuer; Gedeon Perneczky; Govinda S Visvesvara; Horst Aspöck; Norbert Vetter
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more
  31 in total

Review 1.  Nematode phospholipid metabolism: an example of closing the genome-structure-function circle.

Authors:  Soon Goo Lee; Joseph M Jez
Journal:  Trends Parasitol       Date:  2014-03-28

Review 2.  The Global State of Helminth Control and Elimination in Children.

Authors:  Jill E Weatherhead; Peter J Hotez; Rojelio Mejia
Journal:  Pediatr Clin North Am       Date:  2017-08       Impact factor: 3.278

3.  The morphological analysis of autophagy in primary skeletal muscle cells infected with Toxoplasma gondii.

Authors:  Xênia Macedo Souto; Helene Santos Barbosa; Rubem Figueiredo Sadok Menna-Barreto
Journal:  Parasitol Res       Date:  2016-04-14       Impact factor: 2.289

Review 4.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

5.  Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 6.  Enteric protozoa in the developed world: a public health perspective.

Authors:  Stephanie M Fletcher; Damien Stark; John Harkness; John Ellis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

7.  Broad-spectrum Respiratory Virus Entry Inhibitors.

Authors:  Hanjun Zhao; Kwok-Yung Yuen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

8.  Enteric Parasitic Infections in Relation to Diarrhoea in HIV Infected Individuals with CD4 T Cell Counts <1000 Cells/μl in Chennai, India.

Authors:  Anand B Janagond; G Sasikala; David Agatha; Thyagarajan Ravinder; P R Thenmozhivalli
Journal:  J Clin Diagn Res       Date:  2013-10-05

9.  Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling.

Authors:  Kalvin Q Tran; Antony S Tin; Gary L Firestone
Journal:  Anticancer Drugs       Date:  2014-03       Impact factor: 2.248

10.  Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.

Authors:  Luca Braga; Hashim Ali; Ilaria Secco; Elena Chiavacci; Guilherme Neves; Daniel Goldhill; Rebecca Penn; Jose M Jimenez-Guardeño; Ana M Ortega-Prieto; Rossana Bussani; Antonio Cannatà; Giorgia Rizzari; Chiara Collesi; Edoardo Schneider; Daniele Arosio; Ajay M Shah; Wendy S Barclay; Michael H Malim; Juan Burrone; Mauro Giacca
Journal:  Nature       Date:  2021-04-07       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.